



eMAXHealth

eMAX Health
Publications and
References

2017

Peer-reviewed publications

Global

1. **Casciano J**, Doyle J, Casciano R, et al. The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy. *Int J Clin Pract* 2001;55(2):84-92.
2. **Casciano J**, Doyle J, Arikian S, Casciano R. The health economic impact of antidepressant usage from a payer's perspective: A multinational study. *Int J Clin Prac* 2001;55(5):292-9.
3. **Casciano J**, Arikian S, Tarride JE, Doyle JJ, Casciano R. A pharmacoeconomic evaluation of major depressive disorder (Italy). *Epidemiol Psichiatr Soc* 1999;8(3):220-31.
4. Thaulow E, Jorgensen B, Doyle JJ, Casciano R, **Casciano J**, Kopp Z, Arikian S, Kim R. A pharmacoeconomic evaluation of results from the Coronary Angioplasty Amlodipine Restenosis Study (CAPARES) in Norway and Canada. *Int J Cardiol.* 2002 Jul;84(1):23-30; discussion 30-2.
5. Doyle J, Amaya K, **Casciano J**, Kotak S, Buchholz P, Walt J. A disease severity staging system for measuring the cost of glaucoma progression in Europe. *Value in Health* 2002;5(6):552. Abstract.
6. Doyle JJ, McGuire A, Arocho R, Arikian S, **Casciano J**, Svangren P, Casciano R, Kim R, Kugel H. A cost-effectiveness evaluation of amlodipine usage in patients with coronary artery disease in Sweden. *Int J Clin Pract.* 2002 Mar;56(2):76-81.
7. Doyle JJ, **Casciano J**, Arikian S, Tarride JE, Gonzalez MA, Casciano R. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): A comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. *Value in Health* 2001;4(1):16-31.
8. Arikian SR, Ciuryla V, Doyle JJ, **Casciano J**, Casciano R, Hvidsten K. A multinational pharmacoeconomic evaluation of the seven-valent pneumococcal conjugate vaccine. *Value in Health* 2000;3(2):121-2.
9. Doyle JJ, Arikian SR, **Casciano J**, Casciano R, Baleeva J, Gonzalez M. A pharmacoeconomic evaluation of hormone replacement therapy in the United Kingdom and Belgium. *Value in Health* 2000;30(2):100.
10. Bentkover JD, Field C, Greene EM, Plourde V, **Casciano JP**. The economic burden of irritable bowel syndrome in Canada. *Can J Gastroenterol* 1999;13 (Suppl A):89A-96A.

11. Arikian SR, Einarson T, **Casciano J**, Doyle JJ. A health policy analysis of pharmacotherapy for major depressive disorder in Europe and the Americas. In: European College of Neuropsychopharmacology Congress (ECNP); 1998 October; Paris, France: Value in Health, 1998;1 (1):78; 1998.

US Only

12. **Casciano J**, Krishnan J, Buatti-Small M, Li C, **Dotiwala Z**, Martin B. Progression to Uncontrolled Severe Asthma: A novel risk equation. *J Manag Care Spec Pharm*, 2017 Jan;23(1):44-50
13. **Casciano J**, Krishnan J, **Dotiwala Z**, Li C, Sun S. Clinical and Economic Burden of Elevated Blood Eosinophilia in Patients with and without Uncontrolled asthma. *J Manag Care Spec Pharm*, 2017 Jan;23(1):85-91
14. **Casciano J**, Krishnan J, Buatti Small M, Buck P, Gopalan G, Li C, Kemp R, **Dotiwala Z**. Value of peripheral blood eosinophil markers to predict severity of asthma. *BMC Pulmonary Medicine*.2016, 16:109
15. **Casciano J**, Krishnan J, Buatti Small M, Buck P, Gopalan G, Li C, Kemp R, **Dotiwala Z**. Burden of Asthma with Elevated Blood Eosinophil Levels. *BMC Pulmonary Medicine* 2016, 16:100
16. **Casciano J**, **Dotiwala Z**, Kemp R, Li C, Cai J, Preblick R. The Clinical and Economic Burden of Recurrent Venous Thromboembolism. An Inpatient Perspective. *American Journal of Health-System Pharmacy*. February 15, 2015 vol. 72 no. 4 291-300
17. **Casciano J**, **Dotiwala Z**, Martin BC, Kwong W. The Costs of Warfarin Underuse and Nonadherence in Patients with Atrial Fibrillation: A Commercial Insurer Perspective. *J Manag Care Pharm*. 2013;19(4):302-16
18. **Casciano J**, Singer D, Kwong W, Fox E, Martin B. Anticoagulation therapy for patients with non-valvular atrial fibrillation: comparison of decision analytic model recommendations and real-world warfarin prescription use. *American Journal of Cardiovascular Drugs: Drugs, Devices, And Other Interventions*. October 1, 2012;12(5):313-323
19. **Casciano J**, Amaya K, Doyle J, et al. Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails. *Manag Care Interface* 2003;12(3):47-54.

20. **Casciano J**, Arikian SR, Doyle JJ, Casciano R. A managed care validation program for a pharmacoeconomic model of major depression. *Value in Health* 2000;3(2):80.
21. **Casciano J**, Doyle J, Amaya K. Setting reimbursement policy with cost-effectiveness analysis for the treatment of patients with glioblastoma multiform. *Managed Care & Cancer* 2000;2(2):16-22.
22. Schiffman R, Walt J, Jacobsen G, Doyle J, **Lebovics G**, Sumner W. Utility assessment among patients with dry eye disease. *Ophthalmology*. July 2003;110(7):1412-1419.
23. Kelly T, Miao HQ, Yang Y, Navarro E, Kussie P, Huang Y, MacLeod V, **Casciano J**, Joseph L, Zhan F, Zangari M, Barlogie B, Shaughnessy J, Sanderson RD. High heparanase activity in multiple myeloma is associated with elevated microvessel density. *Cancer Res*. 2003 Dec 15;63(24):8749-56.
24. Marin D, Amaya K, Casciano R, Puder KL, **Casciano J**, Chang S, Snyder EH, Cheng I, Cuccia AJ. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease. *Int Psychogeriatr*. 2003 Dec;15(4):385-98.
25. Casciano R, Doyle JJ, Chen J, Arikian S, **Casciano J**, Kugel H, Arocho R. Economic benefits of amlodipine treatment in patients with coronary artery disease. *Pharmacoeconomics*. 2002;20(8):553-63.
26. Serle J, Cantor L, Gross R, Katz J, Mundorf T, Noecker R, Severin T, Simmons S, Walt J, **Casciano J**, Evans S, Doyle J. Best practice treatment algorithm for primary open-angle glaucoma: implications for U.S. ophthalmology practice. *Manag Care Interface*. 2002 Jul;15(7):37-48.
27. Flack JM, Casciano R, **Casciano J**, et al. Cardiovascular disease costs associated with uncontrolled hypertension. *Manag Care Interface* 2002;15(11):28-36.
28. Limentani S, Chin L, **Casciano J**, Casciano R, Evans S, **Lebovics G**. Carmustine implants for glioma cost-effective compared with other innovative oncology treatments. *Oncology* 2002;11(6):33-4.
29. Doyle J, Omvik P, Arikian S, **Casciano J**, Casciano R, Gonzalez MA, Arocho R. A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertension. *Manag Care Interface*. 2001 Mar;14(3):82-7.
30. Thaulow E, Jorgensen B, Doyle JJ, Casciano R, **Casciano J**, Arikian S, Kim R, Arocho R, Kopp Z. A pharmacoeconomic evaluation of amlodipine usage in patients undergoing PTCA in the US

using results from the Coronary Angioplasty Amlodipine Restenosis Study (CAPARES). J Cardiovasc Manag. 2001 Mar-Apr;12(2):31-5. No abstract available.

31. Arikian S, **Casciano J**, Kang-Cipolla L, et al. *The management of depression: The implications for managed care--roundtable discussion: Part 2. Manag Care Interface 2000;(Suppl B):19-25, 32.*
32. Arikian SR, **Casciano JP**, Doyle JJ, Tarride JE, Casciano RN. *A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder. Manag Care Interface 2000;13(2):88-94.*
33. Casciano R, Arikian SR, Tarride JE, **Casciano J**, Doyle JJ. *Antidepressant selection for major depressive disorder: The budgetary impact on managed care. Behavioral Health Trends 2000;12:6-17.*
34. Flack JM, Doyle J, Casciano R, Arocho R, **Casciano J**, Gonzalez M. *The health economic impact of failure to reach blood pressure goals. Am J Hypertension 2000;13:17A-9A.*
35. Arikian SR, Tarride J-E, Casciano R, **Casciano J**. *Determining cost drivers in a cost-effectiveness analysis of three treatments for overactive bladder. Value in Health 1999;2(3):152.*
36. Einarson TR, Arikian SR, **Casciano J**, Doyle JJ. *Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: A meta-analysis of randomized controlled trials. Clin Ther 1999;21(2):296-308.*
37. Doyle JJ, **Casciano JP**, Arikian SR, Mauskopf J, Paul JE. *Full-cost determination of different levels of care in the intensive care unit. An activity-based costing approach. Pharmacoeconomics 1996;10(4):395-408.*

Abstracts and posters

Global

38. **Casciano J**, Doyle JJ, Casciano R, et al. *Cost-effectiveness of doxazosin in combination therapy for hypertension treatment in diabetic patients in the U.K. In: ISPOR; 2000 November; Antwerp, Belgium; 2000.*

39. **Casciano J**, Arikian S, Doyle J, et al. Economic analysis of therapies for onychomycosis of the toenails and fingernails. In: *World Congress of Dermatology 2002 June; Paris, France; 2002.*
40. Doyle J, Amaya K, **Casciano J**, Kotak S, Buchholz P, Walt J. A disease severity staging system for measuring the cost of glaucoma progression in Europe. In: *ISPOR 2002 5th Annual European Congress; 2002; Rotterdam, The Netherlands; 2002.*
41. Ghatte S, Biskupiak J, **Casciano J**, Hagan M, Brixner, D, Rate of Bleeding Events and Comorbidities among Atrial Fibrillation Patients Treated With or Without Warfarin Intl Society of Pharmacoepidemiology, August 2009 Abstract.
42. Arikian SR, **Casciano J**, Doyle JJ, Casciano R, Kim R. A pharmacoeconomic analysis of doxazosin for the treatment of hypertension in diabetic patients in Italy. In: *ESH 2000 June; Gšteborg, Sweden; 2000.*
43. Arikian SR, Ciuryla V, Doyle JJ, **Casciano J**, Casciano R, Hvidsten K. A multinational pharmacoeconomic evaluation of the seven-valent pneumococcal conjugate vaccine. In: *ISPOR 2000 May; Arlington, Virginia; 2000.*
44. Doyle JJ, Arikian SR, **Casciano J**, Casciano R, Baleeva J, Gonzalez M. A pharmacoeconomic evaluation of hormone replacement therapy in the United Kingdom and Belgium. In: *ISPOR; 2000 May; Arlington, Virginia; 2000.*
45. Doyle JJ, Arikian SR, **Casciano J**, Casciano R, Gonzalez M, Kopp Z. A cost comparison study of amlodipine and enalapril in the treatment of hypertension in Europe. In: *ISPOR; 2000 November; Antwerp, Belgium; 2000.*
46. Arikian SR, **Casciano J**, Doyle JJ. Multinational pharmacoeconomics of major depressive disorders. In: *1998 September; Copenhagen, Denmark; 1998.*
47. Arikian SR, **Casciano J**, Doyle JJ. Multinational health economics of major depressive disorders. In: *1998 July; Glasgow, Scotland; 1998.*
48. Arikian SR, **Casciano J**, Doyle JJ. Multinational pharmacoeconomics analysis of major depressive disorders from the prospective of the National Health Service. In: *1998 March; Edinburgh, Scotland; 1998.*
49. Arikian SR, **Casciano J**, Doyle JJ. Pharmacoeconomics of major depressive disorders. In: *Drug Information Association 1998 February; London, United Kingdom; 1998.*

50. Arikian SR, Einarson T, **Casciano J**, Doyle JJ. *The budget impact of pharmacotherapy selection for major depressive disorder: A multinational study. In: ISPOR; 1998 December; Cologne, Germany; 1998.*

US Only

51. **Casciano J, Lebovics G, Dotiwala Z, LaFrance N, Herrera D, Bissonnette S.** *Insurance claims linked medical records review in ~80,000 patients focused on V/Q and CTPA imaging in PE shows that younger women are more likely to receive CTPA: A 10 year retrospective analysis of hospital administrative data. Poster presentation at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June, California, 2016.*
52. **Casciano J, Lebovics G, Dotiwala Z, LaFrance N, Herrera D, Bissonnette S.** *Impact of Ventilation Perfusion Scan and Computed Tomography Pulmonary Angiogram Procedures on Healthcare Resource Use and Cost. Poster presentation at the American college of Radiology Meeting, May, DC, 2016.*
53. **Casciano J, Dotiwala Z, Li C, Sun S.** *Clinical and Economic Burden of Uncontrolled Asthma and Elevated Eosinophil Levels. Oral presentation at the American Thoracic Society Meeting, May, California, 2016.*
54. **Casciano J, Dotiwala Z, Li C, Sun S.** *Clinical and Economic Burden of Uncontrolled Asthma and Elevated Eosinophil Levels. [Abstract] A16. Epidemiology and Health Care Costs of Pediatric and Adult Asthma. May 2016. A1032-A1032*
55. **Casciano J, Dotiwala Z, Li C, Sun S.** *Adherence to Guideline-Recommended Asthma Medication has no impact on Healthcare Resource Utilization and Costs in inadequately controlled asthma patients. Poster presentation at the American Thoracic Society Meeting, May, California, 2016.*
56. **Casciano J, Dotiwala Z, Li C, Sun S.** *Adherence to Guideline-Recommended Asthma Medication has no impact on Healthcare Resource Utilization and Costs in inadequately controlled asthma patients. [Abstract] B48. Asthma: Insights from the bench, genetics, and epidemiology. May 2016. A3715-A3715*
57. **Casciano J, Krishnan J, Buatti-Small M, Li C, Dotiwala Z, Martin B.** *Development and Validation of an Asthma Severity Risk Tool. Poster presentation at the Academy of Managed Care Pharmacy Nexus Meeting, October, Orlando, Florida, 2015.*

58. **Lebovics G, Dotiwala Z, Li C, Schorr A, Kalsekar I, Isupov T, Brun A, Dhankhar P.** Comparison of Comorbidities & Resource Use Between Pramlintide Users & General Type 1 Diabetes Mellitus Population Initiated on Mealtime Insulin. Poster presentation at the American Diabetes Association Annual Meeting, June, Boston, Massachusetts, 2015.
59. **Casciano J, Krishnan J, Buatti-Small M, Li C, Dotiwala Z.** Cost-Consequence of Elevated Versus Normal EOS among Patients that Followed Medication Use Recommended by Guidelines for Severe Asthma. Poster presentation at the International Society For Pharmacoeconomics and Outcomes Research Annual Meeting, May, Philadelphia, Pennsylvania, 2015.
60. **Casciano J, Krishnan J, Buatti-Small M, Bajpai S, Li C, Dotiwala Z.** The association of blood EOS levels with Severe Asthma Defined by 2014 ERS/ATS guidelines. Poster presentation at the American College of Allergy, Asthma, and Immunology Annual Scientific Meeting, November, Atlanta, Georgia, 2014.
61. **Casciano J, Dotiwala Z, Kemp R, Li C, Cai J, Preblich R.** The Clinical and Economic Burden of Recurrent Venous Thromboembolism. An Inpatient Perspective. Poster presentation at the American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition, Orlando, Florida, 2013.
62. **Casciano J, Krishnan J, Buatti-Small M, Buck P, Gopalan G, Li C, Kemp R, Dotiwala Z.** Economic and Clinical Burden of Severe Asthma with Elevated Blood Eosinophil Level. Poster presentation at the American College of Allergy, Asthma, and Immunology Annual Scientific Meeting, November, Baltimore, Maryland, 2013.
63. **Casciano J, Krishnan J, Buatti-Small M, Buck P, Gopalan G, Li C, Kemp R, Dotiwala Z.** The Association of Blood Eosinophil Levels and Asthma Severity in the Midwestern United States. Poster presentation at the American College of Allergy, Asthma, and Immunology Annual Scientific Meeting, November, Baltimore, Maryland, 2013.
64. **Casciano J, Dotiwala Z, Szamreta E, Kwong WJ.** Economic Burden of Warfarin Underutilization in Adults with Nonvalvular Atrial Fibrillation (AF). Poster presented at the Academy of Managed Care Pharmacy Educational Conference, October, Cincinnati, Ohio, 2012.
65. **Martin BC, Casciano JP, Kwong WJ, Singer DE.** Can a Model-Based Decision Support Tool Improve Anticoagulation Outcomes for Atrial Fibrillation? Results from a Large Database

Cohort. Poster presented at the American Heart Association 2011 Scientific Sessions; November 13, Orlando, Florida. 2011.

66. **Casciano J**, Arikian SR, Doyle JJ, Casciano R. A managed care validation program for a pharmacoeconomic model of major depression. In: ISPOR; 2000 May; Arlington, Virginia; 2000.
67. Casciano R, Arikian SR, **Casciano J**, Doyle JJ. Estimating patient level efficacy rates using data expressed at the population level. In: International Conference on Health Policy Research; 1999 December; Santa Monica, California; 1999.
68. Walt J, Doyle J, **Casciano J**, Evans S, Kotak S. The development of a severity staging system for economic of the progression of glaucoma. In: ISPOR; 2002 May; Arlington, Virginia; 2002.
69. Flack JM, Doyle JJ, Casciano R, Arocho R, **Casciano J**, Gonzalez M. The health economic impact of failure to reach blood pressure goals. In: ASH; 2000 May; New York, New York; 2000.
70. Arikian SR, **Casciano J**, Doyle JJ. Evaluating your decisions, portfolio decision-making outcomes. In: Biopharm Conference 1999 June; Philadelphia, Pennsylvania; 1999.
71. Arikian SR, Casciano RN, **Casciano JP**, Doyle JJ. Emerging therapeutic options for overactive bladder: the economics of medicare populations in managed care. In: AMCP 1999 April - May; Minneapolis, Minnesota; 1999.
72. Arikian SR, Tarride J-E, Casciano R, **Casciano J**. Determining cost drivers in a cost-effectiveness analysis of three treatments for overactive bladder. In: ISPOR; 1999 May; Arlington, Virginia; 1999.
73. Arikian SR, **Casciano J**, Doyle JJ. Computer assisted decision analytic modeling. In: ISPOR 1998 May; Philadelphia, Pennsylvania; 1998.
74. Arikian SR, Einarson T, **Casciano J**, Doyle JJ. The budget impact of pharmacotherapies for major depression. In: ASHP; 1998 December; Las Vegas, Nevada; 1998.